Covid-19: FDA authorised and approved drugs and non-vaccine biological products

Updated 22 April, 2022

Source: FDA and corporate websites, compiled by IBMI & RBMP.

Note

1. Baricitinib’s EUA was issued on 19 November, 2020, for the use in hospitalised patients needing intensive care and approved use with remdesivir. FDA broadened the use without remdesivir on 28 July, 2021.
2. Bamlanivimab and Etesevimab’s EUA was issued on 9 February, 2021, for treating patients with mild and moderate Covid-19 symptoms. The EUA was later suspended on 25 June due to the poor viral activity of the treatment against viral variants, on 27 August FDA revised it to be used in areas where infection rate of variants is less than 5 per cent.